Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -1.73% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$7M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -252%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~64.5% on $2M of debt.
Cash of $2M fully covers short-term debt of $1M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 14-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.9× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 18.3 | 9.4 | 8.6 | 3.5 | 40.3 | 65.3 | 56.9 | 0.4 |
| Gross Profit | 81.7 | 90.6 | 91.4 | 96.5 | 59.7 | — | — | — |
| R&D | — | 0.0 | 38.4 | 5.2 | 66.2 | 5.5 | 0.1 | — |
| SG&A | 614.5 | 211.4 | 584.7 | 216.7 | 1213.4 | 247.8 | 123.5 | 112.4 |
| Operating Income | -532.8 | -120.8 | -531.7 | -125.4 | -1292.5 | -224.0 | -101.5 | -105.8 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | 0.9 | 2.1 | -2.2 |
| Net Income | -622.2 | -146.4 | -804.7 | -160.0 | -1324.8 | 266.0 | 138.6 | 340.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on IVF: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M 100.0% | $6.5M 100.0% | $3.0M 100.0% | $822K 100.0% | $4.2M 100.0% | $1.0M 100.0% | $1.5M 100.0% | $494K 100.0% | $282K 100.0% | $51K 100.0% |
| Cost of Revenue | $31K 0.4% | $3.7M 56.9% | $2.0M 65.3% | $332K 40.3% | $145K 3.5% | $89K 8.6% | $140K 9.4% | $90K 18.3% | $52K 18.4% | $15K 29.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $52K 18.4% | $15K 29.7% |
| Gross Profit | — | — | — | $491K 59.7% | $4.0M 96.5% | $949K 91.4% | $1.3M 90.6% | $404K 81.7% | $230K 81.6% | $36K 70.3% |
| Research & Development | — | $5K 0.1% | $166K 5.5% | $544K 66.2% | $216K 5.2% | $398K 38.4% | $0 0.0% | — | — | — |
| Selling, General & Admin | $7.7M 112.4% | $8.1M 123.5% | $7.5M 247.8% | $10.0M 1213.4% | $9.0M 216.7% | $6.1M 584.7% | $3.1M 211.4% | $3.0M 614.5% | $871K 308.6% | $2.1M 4216.5% |
| Total Operating Expenses | $14.1M 205.8% | $14.7M 224.4% | $9.8M 324.0% | $11.4M 1392.5% | $9.2M 221.9% | $6.5M 623.1% | $3.1M 211.4% | $3.0M 614.5% | $871K 308.6% | $2.1M 4216.5% |
| Operating Income | -$7.2M -105.8% | -$6.6M -101.5% | -$6.8M -224.0% | -$10.6M -1292.5% | -$5.2M -125.4% | -$5.5M -531.7% | -$1.8M -120.8% | -$2.6M -532.8% | -$640K -227.0% | -$2.1M -4146.1% |
| Interest Expense | $1.3M 19.0% | $1.1M 16.2% | $926K 30.7% | $59K 7.2% | $1.3M 30.4% | $2.8M 273.5% | $388K 26.2% | $442K 89.4% | $21K 7.4% | $14K 27.2% |
| Interest & Investment Income | — | — | — | — | — | $4K 0.4% | $9K 0.6% | — | — | — |
| Other Income (Expense), net | $1.8M 25.6% | -$972K -14.9% | -$1.2M -41.0% | -$263K -32.0% | -$1.4M -34.5% | -$2.8M -273.1% | -$379K -25.6% | -$442K -89.4% | -$62K -21.9% | — |
| Pretax Income | -$5.5M -80.2% | -$7.6M -116.3% | -$8.0M -265.1% | -$10.9M -1324.5% | -$6.7M -159.9% | -$8.3M -804.7% | -$2.2M -146.4% | -$3.1M -622.2% | -$702K -248.9% | -$2.1M -4173.3% |
| Income Tax Expense | -$150K -2.2% | $140K 2.1% | $28K 0.9% | $3K 0.3% | $5K 0.1% | $36 0.0% | $433 0.0% | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | $23.3M 340.9% | $9.1M 138.6% | $8.0M 266.0% | -$10.9M -1324.8% | -$6.7M -160.0% | -$8.3M -804.7% | -$2.2M -146.4% | -$3.1M -622.2% | -$702K -248.9% | -$2.1M -4173.3% |
| Per Share | ||||||||||
| EPS (Basic) | $-214.64 | $-3782.65 | $-67.37 | $-17.97 | $-0.63 | $-1.52 | $-0.45 | $-0.02 | $0.00 | $-0.02 |
| EPS (Diluted) | $-214.64 | $-3782.65 | $-67.37 | $-17.97 | $-0.63 | $-1.52 | $-0.45 | $-0.02 | $0.00 | $-0.02 |
| Weighted Avg Shares (Basic) | 117K | 3K | 119K | 606K | 10.6M | 5.5M | 4.9M | 147.3M | 141.3M | 139.2M |
| Weighted Avg Shares (Diluted) | 117K | 3K | 119K | 606K | 10.6M | 5.5M | 4.9M | 147.3M | 141.3M | 139.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| IVF | $445382 | — | — | 0.1× | 4.7% | 99.6% | -341% | -323% | -252% | -0.3× | 1 |
Peers = companies sharing IVF's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.